Rosiglitazone and cardiovascular risk: weighing recent evidence.
Stafylas
Panagiotis C
PC
1st Department of Medicine, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece.
Sarafidis
Pantelis A
PA
Lasaridis
Anastasios N
AN
D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone